Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars

NCT01978301 | Terminated Phase 1

• 1 other identifier: 117287
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a 3-arm randomised clinical enabling study, with no investigational product. Keloid patients who are scheduled for surgical excision of one or more keloid scars (up to nine) will be recruited to the study. The aim is to investigate how collagen synthesis within keloid scars is affected by the current approved steroid treatment for keloids, triamcinolone acetonide (TAC). The primary endpoint will be fractional collagen synthesis in keloids which have received intra-lesional injections of TAC, placebo or no treatment prior to their removal. Fractional collagen synthesis will be determined using an established isotope/mass spectrometric technique which measures levels of deuterium incorporation into collagen following administration of heavy water to the subject. In addition; keloid tissue samples will be evaluated post surgery to identify further biomarkers of extracellular matrix synthesis and degradation for application in future clinical studies. Subjects will complete a screening visit and will then be randomised to receive three intra-lesional injections of TAC or placebo, or no treatment, at an interval of 2-3 weeks. Subjects will be randomised to different treatment sequences depending on the number of keloids they have scheduled for surgery, in such a way that subjects with multiple keloids will receive different arms of study treatment in their different keloids. Planned surgery for removal of their keloid(s) will be performed at week 6-8. All subjects will receive daily heavy water (Deuterium oxide) administration (twice daily or thrice daily as directed), with the first dose being taken at the Week 2 clinic visit and the final dose being taken on the day prior to surgery. A follow-up visit will be conducted at 1-4 weeks post-surgery.

Conditions

Fibrosis

Keywords

triamcinolone acetonide (TAC); heavy water; fibrosis; deuterium; collagen degradation; collagen synthesis; Keloid; patient

Outcome Measures

Primary Outcomes (1)

• Fractional synthesis of collagen in keloid scars

  Post surgical excision of keloids, tissue samples will be obtained by snap frozen biopsies. Fractional synthesis of collagen (that is, the fraction of the collagen that is newly synthesised during the labelling period) will be determined using mass spectrometry which measures the levels of deuterium incorporation into hydroxyproline or alanine in the collagen from the excised tissue samples, following administration of heavy water (Deuterium oxide) to the subject

  Week 6-8

Secondary Outcomes (4)

• Keloid scar volume before first dose and immediately prior to surgery

  Day 1 and Week 6-8

• Keloid scar surface area before first dose and immediately prior to surgery

  Day 1 and Week 6-8

• Keloid scar length and height before first dose and immediately prior to surgery

  Day 1 and Week 6-8

• Keloid scar vascularity before first dose and immediately prior to surgery

  Day 1 and Week 6-8

Study Arms (3)

Triamcinolone acetonide

ACTIVE COMPARATOR

Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence

Drug: Triamcinolone acetonide

Placebo

PLACEBO COMPARATOR

Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.

Drug: Placebo

No treatment

NO INTERVENTION

Keloid(s) assigned 'No Treatment' will not receive any treatment.

Interventions

Triamcinolone acetonide DRUG

Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).

Triamcinolone acetonide

Placebo DRUG

Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects have at least one keloid scar scheduled for removal as part of their normal course of treatment
• Males or females aged between 18 and 55 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of: Child-bearing potential with negative pregnancy test as determined by urine human chorionic gonadotropin (hCG) test at screening, AND; agrees not to become pregnant during the course of the study and for at least 1 month after completion of heavy water consumption; OR is of non child-bearing potential
• Male subjects must agree not to father a child during the study and for at least 1 month after completion of heavy water consumption.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

You may not qualify if:

• Keloids to be randomised must not have received steroid treatment for at least two months prior to screening.
• Evidence of other skin conditions or scarring in the region of keloid scaring (including but not limited to: hypertrophic scars, eczema, psoriasis, etc.) unless the Investigator, in consultation with the GSK medical monitor, agree that the condition is unlikely to introduce additional risk factors and will not interfere with the study procedures.
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• History of regular alcohol consumption that could preclude safe completion of the study.
• History of sensitivity to corticosteroids or history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
• Subjects currently receiving oral corticosteroids.
• Subjects with a recent history of tuberculosis (TB) (within last three years).
• Evidence or recent history (past two weeks) of any infection (viral, bacterial, fungal, protozoan, or helminthic).
• History of recurrent fungal infection.
• Lactating females.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

London, E1 2AT, United Kingdom

Location

Related Links

• Results for study 117287 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Fibrosis; Keloid

Interventions

Triamcinolone Acetonide

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Cicatrix

Intervention Hierarchy (Ancestors)

Triamcinolone; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 31, 2013
• First Posted: November 7, 2013
• Study Start: April 15, 2014
• Primary Completion: February 5, 2015
• Study Completion: February 5, 2015
• Last Updated: May 15, 2017

Record last verified: 2017-05

Locations

GB (1)